La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Meridian Bioscience Croissance future
Future contrôle des critères 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Meridian Bioscience.
Informations clés
n/a
Taux de croissance des bénéfices
n/a
Taux de croissance du BPA
Medical Equipment croissance des bénéfices | 17.4% |
Taux de croissance des recettes | n/a |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | n/a |
Mises à jour récentes de la croissance future
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
9/30/2023 | 288 | 35 | N/A | N/A | 2 |
9/30/2022 | 333 | 42 | 74 | 82 | N/A |
6/30/2022 | 344 | 43 | 88 | 95 | N/A |
3/31/2022 | 339 | 62 | 82 | 91 | N/A |
12/31/2021 | 313 | 60 | 59 | 77 | N/A |
9/30/2021 | 318 | 71 | 49 | 67 | N/A |
6/30/2021 | 306 | 71 | 51 | 69 | N/A |
3/31/2021 | 327 | 87 | 60 | 74 | N/A |
12/31/2020 | 299 | 70 | 63 | 68 | N/A |
9/30/2020 | 254 | 46 | 45 | 48 | N/A |
6/30/2020 | 240 | 44 | 36 | 39 | N/A |
3/31/2020 | 204 | 21 | 28 | 31 | N/A |
12/31/2019 | 197 | 19 | 29 | 32 | N/A |
9/30/2019 | 201 | 24 | 32 | 36 | N/A |
6/30/2019 | 203 | 26 | 36 | 40 | N/A |
3/31/2019 | 207 | 27 | 38 | 42 | N/A |
12/31/2018 | 213 | 26 | 35 | 39 | N/A |
9/30/2018 | 214 | 24 | 31 | 35 | N/A |
6/30/2018 | 210 | 24 | 28 | 32 | N/A |
3/31/2018 | 209 | 18 | 26 | 30 | N/A |
12/31/2017 | 206 | 22 | 29 | 34 | N/A |
9/30/2017 | 201 | 22 | 37 | 41 | N/A |
6/30/2017 | 198 | 21 | 39 | 44 | N/A |
3/31/2017 | 199 | 30 | 39 | 44 | N/A |
12/31/2016 | 195 | 30 | 34 | 38 | N/A |
9/30/2016 | 196 | 32 | 33 | 37 | N/A |
6/30/2016 | 195 | 35 | N/A | 38 | N/A |
3/31/2016 | 192 | 36 | N/A | 41 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if VIVO's forecast earnings growth is above the savings rate (2%).
Bénéfices vs marché: Insufficient data to determine if VIVO's earnings are forecast to grow faster than the US market
Croissance élevée des bénéfices: Insufficient data to determine if VIVO's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: Insufficient data to determine if VIVO's revenue is forecast to grow faster than the US market.
Croissance élevée des revenus: Insufficient data to determine if VIVO's revenue is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if VIVO's Return on Equity is forecast to be high in 3 years time